Metabolic / fat-loss

Peptides and related compounds targeting fat loss and metabolic health — from investigational amylin analogues with human trial data to novel-mechanism agents still at the preclinical stage. Each entry states plainly where its evidence sits.

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

5 peptides

Cagrilintide

Human observational

AM833, part of CagriSema

An investigational long-acting amylin analogue, studied alone and combined with semaglutide (CagriSema). Not yet approved.

AOD-9604

Animal / preclinical

hGH fragment 176-191

The fat-loss fragment of human growth hormone, designed to trigger lipolysis without GH's growth and blood-sugar effects. It went through real human trials — a rarity in this category — which found it well tolerated but without meaningful weight loss, so the honest picture here is mixed.

MOTS-c

Animal / preclinical

Mitochondrial ORF of the 12S rRNA-c

A mitochondrial-derived peptide that behaves like an exercise mimetic in rodent studies — improving insulin sensitivity, endurance and fat metabolism — with early human trials underway. One of the more scientifically interesting metabolic peptides.

5-Amino-1MQ

Animal / preclinical

A small-molecule NNMT inhibitor (not strictly a peptide) from academic obesity research, where it shrank fat cells and reduced weight in diet-induced obese mice without appetite suppression. Oral and popular in metabolic stacks; human trials haven't started.

Adipotide

Animal / preclinical

FTPP, Prohibitin-targeting peptide

An experimental targeted peptide designed to kill the blood supply of fat tissue. It produced weight loss in obese primates but also caused kidney toxicity, and it has not progressed to approved human use.